IPO Databook: Decoy Therapeutics (DCOY US) - Oct 2026

91 Views09 Oct 2026 10:00

SUMMARY

Decoy Therapeutics Inc. is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT™ platform, aiming to build a robust portfolio.
Decoy Therapeutics is a pre-clinical stage biotechnology company focused on peptide conjugate therapeutics, with a pipeline including D-MAV candidates and two legacy small molecule clinical candidates.
The company has incurred recurring losses from operations since inception, has not generated product revenue, and faces substantial doubt about its ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream